hydrochlorothiazide has been researched along with Hypercholesterolemia in 22 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 59 patients with mild or moderate essential hypertension effects of propranolol and hydrochlorothiazide on serum lipids, fibrynogen, glucose and uric acid concentrations as well as serum euglobulins fibrynolysis time were studied." | 7.67 | [Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension]. ( Karolko, B; Kawecka, M; Lukasik, S; Moszczyńska, J; Witkowska, M, 1989) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 6.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| "The Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) tested whether (1) the angiotensin-converting enzyme (ACE) inhibitor fosinopril (20 mg per day) was more effective on carotid atherosclerosis progression than the diuretic hydrochlorothiazide (25 mg per day), (2) pravastatin (40 mg per day) was more effective than placebo when added to either hydrochlorothiazide or fosinopril, and (3) there were additive effects of ACE inhibitor and lipid-lowering therapies." | 5.11 | Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. ( Baggio, G; Bond, MG; Crepaldi, G; Gallus, G; Magni, A; Mancia, G; Rubba, P; Sampieri, L; Sperti, G; Veglia, F; Ventura, A; Zanchetti, A, 2004) |
| "The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition." | 5.11 | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005) |
| "Hypertension treatment with doxazosin or HCTZ resulted in a comparable change in arterial IMT after three years, in spite of differences in effect on plasma lipids." | 5.10 | Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. ( Birkenhägeri, JC; de Groot, E; de Heide, LH; de Ridder, MA; Hoogerbrugge, N; Jansen, H; Stijnen, T, 2002) |
| "In 59 patients with mild or moderate essential hypertension effects of propranolol and hydrochlorothiazide on serum lipids, fibrynogen, glucose and uric acid concentrations as well as serum euglobulins fibrynolysis time were studied." | 3.67 | [Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension]. ( Karolko, B; Kawecka, M; Lukasik, S; Moszczyńska, J; Witkowska, M, 1989) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 2.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (36.36) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muñoz, D | 1 |
| Uzoije, P | 1 |
| Reynolds, C | 1 |
| Miller, R | 1 |
| Walkley, D | 1 |
| Pappalardo, S | 1 |
| Tousey, P | 1 |
| Munro, H | 1 |
| Gonzales, H | 1 |
| Song, W | 1 |
| White, C | 1 |
| Blot, WJ | 1 |
| Wang, TJ | 1 |
| Cushman, WC | 1 |
| Goff, DC | 1 |
| Krikken, JA | 1 |
| Waanders, F | 1 |
| Dallinga-Thie, GM | 1 |
| Dikkeschei, LD | 1 |
| Vogt, L | 1 |
| Navis, GJ | 1 |
| Dullaart, RP | 1 |
| Mancia, G | 2 |
| Parati, G | 1 |
| Revera, M | 1 |
| Bilo, G | 1 |
| Giuliano, A | 1 |
| Veglia, F | 2 |
| Crepaldi, G | 2 |
| Zanchetti, A | 3 |
| Yusuf, S | 1 |
| Pais, P | 1 |
| Sigamani, A | 1 |
| Xavier, D | 1 |
| Afzal, R | 1 |
| Gao, P | 1 |
| Teo, KK | 1 |
| Wald, DS | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Hoogerbrugge, N | 1 |
| de Groot, E | 1 |
| de Heide, LH | 1 |
| de Ridder, MA | 1 |
| Birkenhägeri, JC | 1 |
| Stijnen, T | 1 |
| Jansen, H | 1 |
| COHEN, MH | 1 |
| Bond, MG | 1 |
| Gallus, G | 1 |
| Ventura, A | 1 |
| Baggio, G | 1 |
| Sampieri, L | 1 |
| Rubba, P | 1 |
| Sperti, G | 1 |
| Magni, A | 1 |
| Ruilope, LM | 1 |
| Malacco, E | 1 |
| Khder, Y | 1 |
| Kandra, A | 1 |
| Bönner, G | 1 |
| Heintz, D | 1 |
| Cooper-Dehoff, R | 1 |
| Cohen, JD | 2 |
| Bakris, GL | 1 |
| Messerli, FH | 1 |
| Erdine, S | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Pepine, CJ | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Perry, HM | 1 |
| Smith, WM | 1 |
| Chrysant, SG | 1 |
| Neller, GK | 1 |
| Dillard, B | 1 |
| Frohlich, ED | 1 |
| Berioli, S | 1 |
| Bentivoglio, M | 1 |
| Conti, R | 1 |
| Osanna, RA | 1 |
| Savino, K | 1 |
| Zollino, L | 1 |
| Corea, L | 1 |
| Witkowska, M | 1 |
| Lukasik, S | 1 |
| Kawecka, M | 1 |
| Moszczyńska, J | 1 |
| Karolko, B | 1 |
| Siperstein, MD | 1 |
| Sarva, RP | 1 |
| Gavaler, JS | 1 |
| Van Thiel, DH | 1 |
| Ryvkin, IA | 1 |
| Korsunskiĭ, AA | 1 |
| Pribylova, LP | 1 |
| Lobanova, LS | 1 |
| Raĭskaia, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| The SCCS Polypill Pilot Trial[NCT02278471] | Phase 2 | 303 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 109 |
| Polypill | 98 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 108 |
| Polypill | 90 |
polypill-percentage of pills taken, evaluated via pill counts (NCT02278471)
Timeframe: 2 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 98 |
polypill arm-evaluation via pill counts. (NCT02278471)
Timeframe: 12 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 86 |
polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 138 |
| Polypill | 131 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 133 |
| Polypill | 128 |
1 review available for hydrochlorothiazide and Hypercholesterolemia
| Article | Year |
|---|---|
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive | 1997 |
11 trials available for hydrochlorothiazide and Hypercholesterolemia
| Article | Year |
|---|---|
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol Ester Transfer Protei | 2009 |
Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure Determination; Drug Therapy, | 2010 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar | 2012 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular | 2012 |
Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Disease Progression; Diuretics; D | 2002 |
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; C | 2004 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D | 2005 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive | 1997 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide | 1990 |
11 other studies available for hydrochlorothiazide and Hypercholesterolemia
| Article | Year |
|---|---|
More HOPE for Prevention with Statins.
Topics: Antihypertensive Agents; Benzimidazoles; Cardiovascular Diseases; Female; Humans; Hydrochlorothiazid | 2016 |
PROLONGED CARDIOGENIC SHOCK WITH RECOVERY.
Topics: Angina Pectoris; Coronary Disease; Digoxin; Electrocardiography; Hydrochlorothiazide; Hypercholester | 1964 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Some wrong-way chemical changes during antihypertensive treatment: comparison of indapamide and related agents.
Topics: Adult; Antihypertensive Agents; Chemical Phenomena; Chemistry; Chlorthalidone; Diuretics; Humans; Hy | 1983 |
Diuretics and cholesterol elevation.
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Polythia | 1979 |
Effects of diuretics on lipid metabolism in patients with essential hypertension.
Topics: Adult; Blood Glucose; Cholesterol; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; | 1976 |
Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Cholesterol, Dietary; Coronary Disease; Electrocardi | 1992 |
[Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension].
Topics: Adult; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Hydrochlorothiazide; Hype | 1989 |
Type II diabetes: some problems in diagnosis and treatment.
Topics: Blood Glucose; Chlorpropamide; Confusion; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; | 1985 |
Thiazide-induced hypercholesterolemia: sex differences.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cricetinae; Dose-Response Relationship, Drug; Female; Hydroc | 1985 |
[Initial results of the activity of the Angiocardiological Center in Kolomna].
Topics: Adolescent; Adult; Coronary Disease; Diabetes Complications; Female; Heparin; Humans; Hydrochlorothi | 1971 |